Severe Asthma Clinical Trial
Official title:
A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma
This is a randomized, placebo controlled and double blind study to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FB704A in adult patients with severe asthma. The study comprised a 4-week screening period, a 8-week treatment period and a 12-week follow-up period.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | September 30, 2025 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1.18 to ?75 years of age, either sex, any race. 2.Diagnosed as severe asthma based on 2020 GINA guideline. 3.An ACT score is <20. 4.Induced sputum neutrophil count ?50% of total sputum cells during Screening. 5.Documented diagnosis of severe asthma (within past 5 years), and have at least one of the following:?12% and/or 200 mL improvement in Forced Expiratory Volume in 1 second (FEV1) post-bronchodilator, and/or airway hyperresponsiveness (eg, positive methacholine challenge <8 mg/mL). 6.Nonsmoker or previous smoker with cumulative smoking history less than 10 pack-years (pack-year = 20 cigarettes smoked daily for 1 year). Previous smokers may not have smoked within 1 year prior to Screening. A smoker is defined as a subject who has taken inhaled nicotine containing products (e.g. cigarette, cigar, pipe), including e-cigarettes prior to screening. 7.Must not have had a severe asthma exacerbation of asthma for 4 weeks prior to Screening and must be on a stable medication regimen for asthma at least 4 weeks prior to Screening. A Severe asthma exacerbation is defined as a deterioration of asthma leading to treatment for 3 days or more with systemic glucocorticoids or hospitalization or an emergency department visit leading to treatment with systemic glucocorticoids. 8.Must be willing to give written informed consent to participate in the study. 9.Must be capable of complying with the dosing regimen, adhere to the visit schedule, and participate in all treatment procedures, including sputum induction. 10.Female subject of childbearing potential must have a negative serum pregnancy test at Screening and must be using a medically acceptable, highly effective, adequate form of birth control (ie, failure rate <1% per year when used consistently and correctly) prior to Screening and agree to continue using it while in the study (Screening and Treatment Periods). Medically acceptable, highly effective forms of birth control are hormonal implants, oral contraceptives, medically acceptable prescribed intrauterine devices (IUDs), and monogamous relationship with a male partner who has had a vasectomy. Female subject who is not of childbearing potential must have a medical record of being surgically sterile (eg, hysterectomy, tubal ligation), or be at least 1 year postmenopausal. Absence of menses for at least 1 year will indicate that a female is postmenopausal. A female subject should be encouraged to continue using a highly effective method of birth control for 30 days following the end of treatment. Male subject must agree to use an adequate form of contraception for the duration of the study and agree to have sexual relations only with women who use a highly effective birth control method. Exclusion Criteria: 1.Chronic Obstructive Pulmonary Disease (COPD)/other relevant lung disease (other than asthma) 2.4 weeks prior to/or Screening: upper/lower respiratory tract infection 3.Screening: Inadequate amount or difficulty producing sputum 4.Screening: Sputum neutrophil count over 10 million/mL 5.Screening: peripheral blood neutrophil (PBN) count <3000/µL 6.Clinically significant chronic infectious disease(s) (eg, Human Immunodeficiency Virus [HIV], hepatitis B or C) 7.Allergy/sensitivity to study drug/excipients 8.Breast-feeding, pregnant/intends to become pregnant during study 9.Requiring mechanical ventilation for respiratory event within 6 months of Screening 10.Medical condition(s) (eg, hematologic, cardiovascular, renal, hepatic, neurologic, or metabolic) or medication that may interfere with effect of study medication 11.Within 30 days of Screening: any other investigational drug 12.Known history of active tuberculosis (TB) or evidence of tuberculosis infection as defined by a positive purified protein derivative (PPD) skin test and/or interferon-gamma release assay. The interferon-gamma release assay should be repeated in case of an indeterminate result 13.Active infection, including opportunistic infections, requiring systemic therapy within the past 2 weeks 14.A deep space infection within the past 2 years (including, but not limited to meningitis, epiglottitis, endocarditis, septic arthritis, fasciitis, abdominal or pleural abscess, or osteomyelitis) 15.History of diverticulitis, diverticulosis requiring antibiotic treatment, or other symptomatic lower gastrointestinal (GI) conditions that might predispose to perforations 16.Immunization with a live/attenuated vaccine within 4 weeks prior to treatment 17.Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured) 18.Liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 3x upper limit of normal 19.Serum bilirubin > 2x upper limit of normal 20.Low platelet count (<100,000/mm3) 21.Dyslipidemia 22.Participation in any other clinical study 23.Part of the staff personnel involved with the study 24.Family member of investigational study staff |
Country | Name | City | State |
---|---|---|---|
Taiwan | NTUH Hsin-Chu Branch | Hsinchu | |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | China Medical University Hospital | Taichung city | |
Taiwan | Ministry of Health and Welfare Shuang-Ho Hospital | Taipei | |
Taiwan | Taipei Medical University Hospital | Taipei | |
Taiwan | Taipei Municipal Wanfang Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Oneness Biotech Co., Ltd. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in IL-6 | IL-6 | during the study (8 weeks treatment period and 12 weeks follow up | |
Primary | Proportion of the number of Adverse Event reported during the treatment period | AE | Day 57 | |
Secondary | Change from baseline in blood neutrophil counts | neutrophil counts | Day 36, 57, 85, 113, and 141 | |
Secondary | Change from baseline in sputum neutrophil counts | neutrophil counts | Day 57 | |
Secondary | ACT score | The ACT Score > 19 means well controlled. | Day 36, 57, 85, and 141 | |
Secondary | Change from baseline in Asthma control test (ACT) | The ACT Score > 19 means well controlled. | Day 36, 57, 85, and 141 | |
Secondary | Percentage of patients achieving decrease in score by greater than or equal to 0.5 points on the ACQ 5 (with a minimal importance difference improvement) | The Asthma symptom score and 5 item Asthma Control Questionnaire (ACQ 5) will be applied to evaluate the condition of asthma control. Subjects will perform the test. | week 4, 8, 12, and 20 | |
Secondary | Change from baseline in ACQ-5 | The Asthma symptom score and 5 item Asthma Control Questionnaire (ACQ 5) will be applied to evaluate the condition of asthma control. Subjects will perform the test. | Day 36, 57, 85, and 141 | |
Secondary | Change from baseline in AQLQ | Standardized Asthma Quality of Life Questionnaire (AQLQ) will be applied to evaluate the asthma specific quality of life. | Day 36, 57, 85, and 141 | |
Secondary | Change from baseline in pre-bronchodilator FEV1 , post-bronchodilator FEV1, exhaled NO and asthma symptoms | Forced expiratory volume in 1 second (FEV1) is the volume exhaled during the first second of a forced expiratory maneuver started from the level of total lung capacity. Spirometry testing must be performed in the morning between 6 11 am according to the schedule of study procedures. After the first screening spirometry completed, the | Day 57 and 141 | |
Secondary | Proportion of the number of AE reporting (incidence of adverse event) | AE | 12 weeks follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05472324 -
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
|
Phase 2 | |
Recruiting |
NCT04914078 -
Severe Asthma Exacerbations and Mepolizumab Treatment
|
||
Completed |
NCT05576454 -
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
|
Phase 1 | |
Recruiting |
NCT04520165 -
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
|
||
Recruiting |
NCT04438408 -
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
|
||
Not yet recruiting |
NCT04463836 -
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
|
||
Enrolling by invitation |
NCT06421402 -
K-HEALTH in AIR - Barcelona Pilot - Cohort
|
||
Recruiting |
NCT03377920 -
Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.
|
N/A | |
Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
Recruiting |
NCT04045587 -
International Severe Asthma Registry: Canadian Cohort
|
||
Completed |
NCT05616338 -
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
|
N/A | |
Active, not recruiting |
NCT02038374 -
Clinico-biological Correlation of Severe Asthma in Children
|
N/A | |
Active, not recruiting |
NCT02114034 -
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
|
||
Recruiting |
NCT06035289 -
Register Schweres Asthma - German Asthma Net e.V.
|
||
Not yet recruiting |
NCT03532685 -
Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up
|
N/A | |
Completed |
NCT03931954 -
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
|
||
Recruiting |
NCT03984253 -
Swiss Severe Asthma Register
|
||
Recruiting |
NCT03435237 -
Phenotyping Asthma for Bronchial Thermoplasty
|
||
Recruiting |
NCT03476109 -
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
|
Phase 4 | |
Active, not recruiting |
NCT06389058 -
Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System
|